15 results
10-Q
2023 Q1
EX-10.1
COYA
Coya Therapeutics Inc
10 May 23
Quarterly report
7:14am
Party’s liability for death or personal injury caused by its gross negligence, or that of its employees, agents, or sub-contractors (as applicable); fraud
10-K
2022 FY
COYA
Coya Therapeutics Inc
29 Mar 23
Annual report
4:08pm
by inflammation, cellular injury, and fibrosis, which can lead to cirrhosis and hepatocarcinoma.
The accumulation of lipid deposits in hepatocytes … in recognizing or managing the potential side effects of our product candidates could result in patient injury or death.
We may seek special designations
424B4
COYA
Coya Therapeutics Inc
30 Dec 22
Prospectus supplement with pricing info
4:17pm
effects of our product candidates could result in patient injury or death.
We may seek special designations by the regulatory authorities to expedite … ;
the inability to commercialize any product candidate that we may develop; and
injury to our reputation and significant negative media attention.
Any
S-1/A
EX-10.12
vnpgs5
5 Dec 22
IPO registration (amended)
8:16am
S-1/A
iosqfhc3yxzl3
5 Dec 22
IPO registration (amended)
8:16am
S-1/A
EX-10.7
13egc6s 769gwwp
5 Dec 22
IPO registration (amended)
8:16am
S-1
EX-10.12
vxivn6g o7d9
18 Nov 22
IPO registration
5:06pm
S-1
7op7 he2t0vrr9
18 Nov 22
IPO registration
5:06pm
S-1
EX-10.7
o4q1fd8
18 Nov 22
IPO registration
5:06pm
DRS/A
hvyv juqskiqa8p5cv
28 Oct 22
Draft registration statement (amended)
12:00am
DRS/A
j3jstw8r91f6q9htmu3n
7 Oct 22
Draft registration statement (amended)
12:00am
DRS
j80n13f7v 6zm
19 Aug 22
Draft registration statement
12:00am
- Prev
- 1
- Next